INT2064

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1977
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 29
Total Number 29
Disease Relevance 25.58
Pain Relevance 15.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (BTG3)
Anatomy Link Frequency
blood 1
liver 1
pleural fluid 1
leukocyte 1
BTG3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Infliximab 935 99.98 Very High Very High Very High
spinal inflammation 620 99.76 Very High Very High Very High
rheumatoid arthritis 1257 99.62 Very High Very High Very High
Adalimumab 171 98.72 Very High Very High Very High
methotrexate 205 98.12 Very High Very High Very High
fibrosis 7 97.24 Very High Very High Very High
Arthritis 137 93.80 High High
Inflammation 78 93.64 High High
Multiple sclerosis 7 92.24 High High
Angina 4 89.24 High High
Disease Link Frequency Relevance Heat
Low Back Pain 611 99.76 Very High Very High Very High
Rheumatoid Arthritis 1257 99.62 Very High Very High Very High
Seronegative Spondarthritis 73 99.62 Very High Very High Very High
Disease 283 99.08 Very High Very High Very High
Systemic Lupus Erythematosus 210 98.86 Very High Very High Very High
Toxicity 9 98.14 Very High Very High Very High
Liver Disease 6 98.14 Very High Very High Very High
Fibrosis 6 97.24 Very High Very High Very High
Immune System Diseases 3 95.16 Very High Very High Very High
Pleurisy 3 93.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Patient had no symptoms/signs that can meet the SLE criteria; however, immunological workup showed positive response of ANA-speckle, anti-dsDNA, and anti-ENA in patient serum and pleural fluid.
Positive_regulation (response) of ANA in pleural fluid associated with systemic lupus erythematosus
1) Confidence 0.49 Published 2008 Journal Rheumatol. Int. Section Abstract Doc Link 18496695 Disease Relevance 1.44 Pain Relevance 0.17
After 12 months of therapy, induction of ANA was observed in 16 of 57 (28%) adalimumab-treated patients with RA, and in 8 of 55 (14.5%) with methotrexate only (Table 5).
Positive_regulation (induction) of ANA associated with rheumatoid arthritis, adalimumab and methotrexate
2) Confidence 0.36 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0.29 Pain Relevance 0.56
The induction of ANA and aPL autoantibodies was clearly due to infliximab, especially in the RA group, because no such induction was observed in the control RA group treated with methotrexate alone.
Positive_regulation (induction) of ANA associated with infliximab, rheumatoid arthritis and methotrexate
3) Confidence 0.35 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC1064868 Disease Relevance 0.90 Pain Relevance 0.63
The difference between the number of induced ANA compared with the number of positive ANA at baseline was statistically significant (P < 0.0001) for infliximab-treated RA and AS patients, whereas the difference was not significant for the RA control group.
Positive_regulation (induced) of ANA associated with spinal inflammation, infliximab and rheumatoid arthritis
4) Confidence 0.31 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC1064868 Disease Relevance 1.70 Pain Relevance 1.42
Except in two RA patients, all the induced ANA were still positive at the end of the study, including in eight of nine patients who discontinued the treatment.
Neg (Except) Positive_regulation (induced) of ANA associated with rheumatoid arthritis
5) Confidence 0.31 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC1064868 Disease Relevance 1.94 Pain Relevance 1.62
The induction of ANA appeared between 3 and 18 months (mean 6.35 months) for RA and between 3 and 24 months (mean 10.6 months) for AS.
Positive_regulation (induction) of ANA associated with spinal inflammation and rheumatoid arthritis
6) Confidence 0.31 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC1064868 Disease Relevance 1.99 Pain Relevance 1.63
Induction of ANA, low-titer IgG/IgM anti-dsDNA but not aPL seems to be a drug-class-related effect, because increased antibody levels were found during treatment; however, no related clinical manifestations were recorded and antibody frequency was found to be lower than in studies with other TNF blocking agents.


Positive_regulation (Induction) of ANA
7) Confidence 0.24 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0.39 Pain Relevance 0.13
A significant induction of antinuclear autoantibodies (ANA) and IgG/IgM anti-dsDNA autoantibodies were also found in 28% and 14.6% patients, respectively, whereas aCL and anti-?
Positive_regulation (induction) of ANA
8) Confidence 0.24 Published 2006 Journal Arthritis Res Ther Section Abstract Doc Link PMC1526573 Disease Relevance 0.39 Pain Relevance 0.38
Sera positive for ANA by indirect immunofluorescence were further analysed for the presence of anti-extractable nuclear antigens (anti-ENA) by Addressable Laser Bead Immunoassays (Menarini Diagnostics) in accordance with the manufacturer's instructions [28].
Positive_regulation (positive) of ANA
9) Confidence 0.24 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0 Pain Relevance 0.08
Immunofluorescent studies were conducted for leukocyte-reactive antinuclear antibody (LR-ANA) with sera from 125 patients with ankylosing spondylitis (as), 124 with rheumatoid arthritis (RA) 74 with miscellaneous immune disorders (MID), 34 with acute inflammatory disorders (AID) and 122 non-immune controls.
Positive_regulation (conducted) of LR-ANA in leukocyte associated with spinal inflammation, inflammation, rheumatoid arthritis and immune system diseases
10) Confidence 0.24 Published 1977 Journal J. Rheumatol. Section Abstract Doc Link 328881 Disease Relevance 0.80 Pain Relevance 0.36
Our results confirmed the occurrence of ANA and anti-dsDNA autoantibodies and demonstrated that the induction of ANA, anti-dsDNA and aPL autoantibodies is related to infliximab treatment in both RA and AS, with no significant relationship to clinical manifestations.



Positive_regulation (induction) of ANA associated with spinal inflammation, infliximab and rheumatoid arthritis
11) Confidence 0.23 Published 2004 Journal Arthritis Res Ther Section Abstract Doc Link PMC1064868 Disease Relevance 1.24 Pain Relevance 1.05
The titer of ANA showed a higher level between the positive ANA at the baseline compared with the titer of induced ANA, but the difference was not significant.
Positive_regulation (induced) of ANA
12) Confidence 0.22 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC1064868 Disease Relevance 1.41 Pain Relevance 1.21
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

Treatment of rheumatoid arthritis (RA) with infliximab (Remicade®) has been associated with the induction of antinuclear autoantibodies (ANA) and anti-double-stranded DNA (anti-dsDNA) autoantibodies.

Positive_regulation (induction) of ANA associated with spinal inflammation, infliximab and rheumatoid arthritis
13) Confidence 0.20 Published 2004 Journal Arthritis Res Ther Section Title Doc Link PMC1064868 Disease Relevance 1.28 Pain Relevance 1.13
Infliximab led to a significant induction of ANA and anti-dsDNA autoantibodies in 86.7% and 57% of RA patients and in 85% and 31% of AS patients, respectively.
Positive_regulation (induction) of ANA associated with spinal inflammation, infliximab and rheumatoid arthritis
14) Confidence 0.20 Published 2004 Journal Arthritis Res Ther Section Abstract Doc Link PMC1064868 Disease Relevance 1.32 Pain Relevance 1.15
After 12 months of therapy, the induction of ANA was observed in 12 infliximab-treated RA patients, 8 AS patients and 4 control RA patients.
Positive_regulation (induction) of ANA associated with spinal inflammation, infliximab and rheumatoid arthritis
15) Confidence 0.20 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC1064868 Disease Relevance 1.25 Pain Relevance 1.04
Our results show that infliximab induces ANA, anti-dsDNA and aPL autoantibodies at various times after the start of treatment.
Positive_regulation (induces) of ANA associated with infliximab
16) Confidence 0.20 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC1064868 Disease Relevance 0.87 Pain Relevance 0.34
The percentage of subjects having a positive ANA at a titer ?
Positive_regulation (positive) of ANA
17) Confidence 0.17 Published 2005 Journal Environ Health Perspect Section Body Doc Link PMC1253705 Disease Relevance 0 Pain Relevance 0
Again, the data showed increasing ANA titer with increasing disease severity.
Positive_regulation (increasing) of ANA associated with disease
18) Confidence 0.17 Published 2005 Journal Environ Health Perspect Section Body Doc Link PMC1253705 Disease Relevance 0.75 Pain Relevance 0.08
Increased serum immunoglobulins, positive antinuclear antibody (ANA) tests, and immune complexes have been reported in small cohorts of individuals exposed to asbestos (Lange 1980; Nigam et al. 1993; Zerva et al. 1989), but to our knowledge no comprehensive study has been undertaken to assess the prevalence, specificity, and significance of autoantibodies associated with asbestos exposures.
Positive_regulation (Increased) of ANA
19) Confidence 0.17 Published 2005 Journal Environ Health Perspect Section Body Doc Link PMC1253705 Disease Relevance 0.90 Pain Relevance 0.13
One subject of Groups I (1.3%) and II (1.7%), respectively had high serum levels of ANA, while none of the subjects in Group III had serum ANA.
Positive_regulation (had) of ANA
20) Confidence 0.10 Published 2006 Journal Journal of Korean Medical Science Section Body Doc Link PMC2729943 Disease Relevance 0.28 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox